© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 13, 1030-1031,
July 5, 2000
© 2000 Oxford University Press
EDITORIALS |
Promiscuous Transcription of Vascular Endothelial Growth Factor and Survival of Tumors
Affiliations of authors: L. M. Ellis (Departments of Surgical Oncology and Cancer Biology), G. E. Gallick (Department of Cancer Biology), The University of Texas M.D. Anderson Cancer Center, Houston.
Correspondence to: Lee M. Ellis, M.D., Department of Surgical Oncology, Box 106, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (e-mail: lellis@mdanderson.org).
Angiogenesis, the process of formation of new blood vessels, is among the most active areas of research, not only in the field of cancer but also in the fields of developmental biology, cardiovascular disease, diabetes, and rheumatology. Until recently, there has been a great divide between the expansion of knowledge obtained by basic science investigations and clinical application. By necessity, various factors, including economic forces and patient advocacy, have provoked investigators to become increasingly aware of the need to interpret basic science findings in light of potential clinical applications.
In this issue of the Journal, Sheta et al. (1) have demonstrated that cellcell
NOTES
REFERENCES